Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics (CuraTeQ) has received marketing authorisation under Form CT 23 from Central Drugs Standard Control Organization (CDSCO) for Bevqolva, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva in 100 mg/4mL and 400 mg/16 mL vial presentations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
